abstract |
It is intended to provide a medicinal composition (in an appropriate case, a remedy and/or a preventive for diabetes) containing a combination of a GLP-1 receptor activator with 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidin-2,4-dione, which is an agent improving insulin resistance, or a pharmacologically acceptable salt thereof. |